Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback